ESMO 2025: Precision Medicine Trial Shows Promise in Rare Cancers

The IMPRESS Norway trial, presented by Katarina Puco, MD, at ESMO 2025, explores targeted treatment options for patients with advanced rare cancers who have exhausted standard therapies. Of the 1,125 patients analyzed, 28% harbored actionable biomarkers, enabling inclusion in specific treatment cohorts. Nearly half of the 176 patients who received targeted therapy achieved clinical benefit after 16 weeks. The findings emphasize tumor diversity and variable treatment responses, highlighting the importance of international collaboration, such as the EU Cancer Mission Project Primrose, to facilitate broader access and regulatory approvals for these therapies.